Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

The impact of comorbidity on mortality in Danish sarcoma patients from 2000-2013: A nationwide population-based multicentre study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Dancing with atrial fibrillation - How arrhythmia affects everyday life of family members: A qualitative study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Insulin resistance genetic risk score and burden of coronary artery disease in patients referred for coronary angiography

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Genetic markers of abdominal obesity and weight loss after gastric bypass surgery

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. No detectable remodelling in adult human menisci: an analysis based on the C14 bomb pulse

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. In vitro 4-1BB stimulation promotes expansion of CD8+ tumor-infiltrating lymphocytes from various sarcoma subtypes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

INTRODUCTION: Sarcoma is a rare type of cancer. The incidence increases with age and elderly patients may have comorbidity that affects the prognosis. The aim of this study was to describe the type and prevalence of comorbidity in a nationwide population-based study in Denmark from 2000-2013 and to analyse the impact of the different comorbidities on mortality.

MATERIAL AND METHODS: The Danish Sarcoma Registry is a national clinical database containing all patients with sarcoma in the extremities or trunk wall from 2000 and onwards. By linking data to other registries, we were able to get patient information on an individual level including date and cause of death as well as the comorbidity type up to 10 years prior to the sarcoma diagnosis. Based on diseases in the Charlson Comorbidity Index, we pooled the patients into six categories: no comorbidity, cardiopulmonary disease, gastrointestinal disease, neurovascular disease, malignant neoplasms, and miscellaneous (diabetes, renal and connective tissue diseases). 2167 patients were included.

RESULTS: The prevalence of comorbidity was 20%. For patients with localized disease, comorbidity increased the disease-specific mortality significantly (HR 1.70 (95% CI 1.36-2.13)). For patients with metastatic disease at the time of diagnosis, comorbidity did not affect the disease-specific mortality (HR 1.05 (95% CI 0.78-1.42)). The presence of another cancer diagnosis within 10 years prior to the sarcoma diagnosis was the only significant independent prognostic factor of disease-specific mortality with an increase of 66% in mortality rate compared to patients with no comorbidity (HR 1,66 (95% CI 1.22-2.25)).

CONCLUSION: Comorbidity is a strong independent prognostic factor of mortality in patients with localized disease. This study emphasizes the need for optimizing the general health of comorbid patients in order to achieve a survival benefit from treatment of patients with localized disease, as this is potentially modifiable.

OriginalsprogEngelsk
TidsskriftPLoS One
Vol/bind13
Udgave nummer6
Sider (fra-til)e0198933
ISSN1932-6203
DOI
StatusUdgivet - 2018

ID: 56461403